IL2 and acute myeloid leukemia: In this regard, a clinical phase II trial of maintenance therapy with HDC plus IL-2 after chemotherapy in AML patients has shown reduced relapse rates [18], however the effects of the treatment on NK cells have not been investigated in detail in this study.